Robotics as Infrastructure: Designing the Next Operating Model for Healthcare

Updated on January 1, 2026
Artificial intelligence, Healthcare, Robots in Healthcare, Healthcare Technology

In recent years, healthcare has seen a quiet but profound shift take place in the operating room. Surgical robots have become more and more ubiquitous, with nearly 10,000 robots now operating regularly on patients across hospitals large and small across the US. Until now, robots have always been purely extensions of the surgeon’s hands, allowing a surgeon to operate with greater precision, stability and care. 

That is starting to change. A growing body of research shows that surgical robotics is gradually but steadily advancing toward greater autonomy. Just as we have seen gradual but consistent progress in self-driving cars and automated manufacturing, robots are beginning to be capable of executing targeted procedural steps under surgeon supervision rather than mere manual control. What was once a futuristic aspiration is becoming a budding clinical reality: surgical systems that can anticipate and adapt to a surgeon’s needs in real time.

As hospitals face mounting pressures — staffing shortages, growing patient demand, and the imperative to deliver safer, more sustainable care — robotics is emerging not only as an innovation, but as an infrastructure solution. Each incremental step toward autonomy redefines what’s possible in procedural precision, safety, and efficiency, setting the stage for healthcare models that are more resilient, scalable, and human-centered than ever before.

Three Key Areas of Improvement Robotics Is Enabling 

1. Precision and Predictability

Surgical precision is no longer a matter of skill alone, it’s a function of systems design. Robotic platforms now enable ultra-fine control, minimizing tremor, standardizing motion, and integrating imaging and diagnostic data directly into procedural workflows. The result: fewer complications, reduced radiation exposure, and shorter recovery times. For hospital executives, that translates to measurable gains such as improved patient outcomes, lower readmissions, and stronger quality metrics that directly influence reimbursement and reputation.

Recent evidence supports these trends:

  • A large randomized multicenter trial published in JAMA found that robotic surgery for rectal cancer reduced local recurrence rates by more than half compared to laparoscopic procedures — underscoring the precision advantages of robotic systems.
  • Similarly, a national analysis in JAMA Surgery reported fewer conversions to open operations and shorter hospital stays for patients treated with robotic-assisted approaches.
  • Complementary research in BMJ Open, synthesizing more than 160 systematic reviews, concluded that robotic surgery generally achieves outcomes equivalent or superior to conventional minimally invasive techniques across most intracavity procedures.

2. Efficiency and Workforce Sustainability

The most immediate impact of robotics may be operational. By automating repetitive or ergonomically demanding tasks, robotics may help offset staffing shortages and burnout. Automation allows skilled clinicians to work at the top of their license, while predictive analytics and AI-driven guidance reduce procedural variability and turnover times. For leaders balancing cost and capacity, robotics offers a sustainable lever to expand throughput without expanding headcount.

3. Integration and Insight

Modern robotic systems are evolving into data hubs that capture, analyze, and relay information across the surgical ecosystem. In the electrophysiology lab where our robots are used, this means integrating various patient-specific diagnostic data such as mapping, electrograms, fluoroscopy, and preoperative imaging, to support intraoperative decision making. Looking forward, it can mean combining intraoperative analytics with postoperative insights to inform continuous improvement. These data loops will define the next era of performance management — supporting clinical and operational excellence.

Collectively, these advancements represent more than a technological upgrade; they’re reshaping the clinical and business model of modern care. The question for healthcare leaders is no longer whether to integrate robotics, but how to design for it: aligning technology, workforce, and patient strategy to realize its full potential.

From Devices to Ecosystems: The Next Phase of Robotic Integration

As hospitals confront growing procedural demand, rising labor costs, and tightening reimbursement, robotics is emerging as a pragmatic solution to systemic strain. The opportunity ahead lies in designing integration strategies that align robotic capabilities with institutional goals: improving throughput, strengthening safety metrics, and optimizing workforce utilization.

To do that, leaders must think beyond device acquisition. A robotics program is an ecosystem: encompassing workflow redesign, data governance, training, and interdisciplinary collaboration. Executives who frame robotics as part of a broader operational strategy will create measurable returns (e.g., reduced variance, lower turnover, and scalable quality across service lines).

The operating environments are becoming living laboratories for this transformation. Those who invest today in adaptive infrastructure won’t just keep pace with innovation; they’ll define the operational blueprint for a safer, more sustainable model of care.

Ultimately, the story of surgical robotics is a story of human ingenuity: of clinicians leveraging technology not to replace their judgment, but to enhance and extend it. As automation matures, the institutions that thrive will be those that design for adaptability: where data, devices, and people collaborate seamlessly to deliver precision care that is not only smarter, but profoundly more human.

David Fischel
David Fischel
CEO and Chairman at Stereotaxis

David Fischel has served as CEO and Chairman of the Board of Stereotaxis since February 2017 after previously serving as Director, having orchestrated the equity investment and positive strategic initiatives announced in September 2016. He previously served as Principal and portfolio manager for medical device investments at DAFNA Capital Management, LLC for over eight years. In addition to his research responsibilities, David has been deeply involved in all aspects of the firm’s operations including legal, accounting, IT, compliance, human resources and marketing. Prior to joining DAFNA Capital, he was a research analyst at SCP Vitalife, a healthcare venture capital fund. David completed his B.S. magna cum laude in Applied Mathematics with a minor in Accounting at the University of California at Los Angeles and received his MBA from Bar-Ilan University in Tel Aviv.